Jose Rubio-Briones
Overview
Explore the profile of Jose Rubio-Briones including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
759
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Guinot J, Casanova J, Gonzalez-Perez V, Santos M, De Los Dolores V, Tortajada M, et al.
J Contemp Brachytherapy
. 2022 Oct;
14(3):215-221.
PMID: 36199987
Purpose: Brachytherapy (BT) with iodine-125 (I) seeds is effective in low- and intermediate-risk prostate carcinoma, with fewer side effects compared to other techniques, but relapses increase in long-term. In the...
12.
Claps F, de Pablos-Rodriguez P, Gomez-Ferrer A, Mascaros J, Marenco J, Collado Serra A, et al.
Urol Oncol
. 2022 Sep;
40(11):489.e19-489.e26.
PMID: 36175317
Introduction And Objectives: Extended Pelvic Lymph Node Dissection (ePLND) remains the most accurate technique for the detection of occult lymph node metastases (LNMs) in prostate cancer (CaP) patients. Here we...
13.
Crocerossa F, Autorino R, Derweesh I, Carbonara U, Cantiello F, Damiano R, et al.
Minerva Urol Nephrol
. 2022 Sep;
75(1):1-16.
PMID: 36094386
Introduction: After transplantation, approximately 10% of renal cell carcinomas are detected in graft kidneys. These tumors (gRCC) present surgeons with the difficulty of finding a treatment that guarantees both oncological...
14.
Marenghi C, Qiu Z, Helleman J, Nieboer D, Rubio-Briones J, Carroll P, et al.
Cancers (Basel)
. 2022 Jul;
14(15).
PMID: 35892817
Background: Little is known about the consequences of delaying radical prostatectomy (RP) after Active Surveillance (AS) according to stringent or wider entry criteria. We investigated the association between inclusion criteria...
15.
Alegre-Martinez A, Martinez-Martinez M, Rubio-Briones J, Cauli O
Diseases
. 2022 Jul;
10(3).
PMID: 35892733
Nickel is associated with cancer in occupational exposure. However, few studies have been devoted to analyzing the effects of nickel at environmental concentrations in cancer patients. In this work, the...
16.
Remmers S, Helleman J, Nieboer D, Trock B, Hyndman M, Moore C, et al.
Eur Urol Open Sci
. 2022 Jul;
41:126-133.
PMID: 35813247
Background: Active surveillance (AS) is a management option for men diagnosed with low-risk prostate cancer. Opinions differ on whether it is safe to include young men (≤60 yr) or men...
17.
Beijert I, Hentschel A, Brundl J, Comperat E, Plass K, Rodriguez O, et al.
Eur Urol Focus
. 2022 May;
8(6):1627-1634.
PMID: 35577750
Background: The pathological existence and clinical consequence of stage T1 grade 1 (T1G1) bladder cancer are the subject of debate. Even though the diagnosis of T1G1 is controversial, several reports...
18.
Lopez-Guerrero J, Pastor-Navarro B, Claramunt-Alonso R, Garcia-Flores M, Rubio-Briones J
Arch Esp Urol
. 2022 Mar;
75(2):203-214.
PMID: 35332890
In the recent years, research in oncologyhas focused on liquid biopsies, which rely on thedetection of cancer-derived components, includingcirculating tumor cells (CTCs), circulating tumor DNA(ctDNA), circulating free RNA (cfRNA), and...
19.
Pastor-Navarro B, Rubio-Briones J
Arch Esp Urol
. 2022 Mar;
75(2):173-184.
PMID: 35332887
Introduction And Objectives: Active surveillance (AS) is currently a therapeuticstrategy recommended by all Clinical Guidelines forthe initial management of very low-risk, low-risk, andsome intermediate-risk prostate cancer (PCa). However,a high percentage...
20.
Claps F, Mir C, Rubio-Briones J
Arch Esp Urol
. 2022 Mar;
75(2):144-155.
PMID: 35332884
Predicting response to definitive treatmentsis a fascinating challenge which develops throughthe evolution of a panel of convincing molecularbiomarkers capable of adding in clinical decissionsdespite interpatient and intratumoral heterogenicity.Muscle-invasive bladder cancer...